Aurobindo Pharma Ltd (AUROPHARMA) Price & Analysis

Compare

1 Followers

AUROPHARMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹994.35 - ₹1,592.55

Previous CloseN/A

Volume696.31K

Average Volume (3M)41.91K

Market Cap

₹607.11B

Enterprise Value₹864.15B

Total Cash (Recent Filing)₹82.36B

Total Debt (Recent Filing)₹82.63B

Price to Earnings (P/E)17.9

Beta1.05

Next Earnings

Nov 12, 2025

EPS Estimate

15.58

Last Dividend Ex-Date

Aug 08, 2025

Dividend Yield0.38%

Share Statistics

EPS (TTM)14.20

Shares Outstanding580,801,640

10 Day Avg. Volume60,060

30 Day Avg. Volume41,913

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,215.17

Price Target Upside16.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Aurobindo Pharma Ltd News

Aurobindo Pharma’s Apitoria Unit Completes US FDA Inspection with Procedural Observations

The latest update is out from Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ). Aurobindo Pharma Limited announced the completion...

3h ago

Aurobindo Pharma to Engage in Virtual Investor Conference

Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ) just unveiled an update. Aurobindo Pharma Ltd has announced its participation in...

17d ago

CuraTeQ Biologics Gains EMA Positive Opinion for Dazublys®

Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ) just unveiled an update. CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has...

4M ago

Aurobindo Pharma’s Eugia Pharma Gains USFDA Approval for Dasatinib Tablets

Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ) has shared an announcement. Aurobindo Pharma Limited announced that its subsidiary, Eugia...

4M ago

Aurobindo Pharma Secures USFDA Approval for Rivaroxaban Tablets

Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ) has issued an announcement. Aurobindo Pharma Limited has received final approval from...

5M ago

Aurobindo Pharma’s US Warehouse Receives OAI Status Post FDA Inspection

The latest announcement is out from Aurobindo Pharma Ltd ( ($IN:AUROPHARMA) ). Aurobindo Pharma Ltd announced that an...

6M ago

AUROPHARMA FAQ

What was Aurobindo Pharma Ltd’s price range in the past 12 months?

Aurobindo Pharma Ltd lowest stock price was ₹994.35 and its highest was ₹1592.55 in the past 12 months.

What is Aurobindo Pharma Ltd’s market cap?

Aurobindo Pharma Ltd’s market cap is ₹607.11B.

When is Aurobindo Pharma Ltd’s upcoming earnings report date?

Aurobindo Pharma Ltd’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.

How were Aurobindo Pharma Ltd’s earnings last quarter?

Aurobindo Pharma Ltd released its earnings results on Aug 04, 2025. The company reported ₹14.2 earnings per share for the quarter, missing the consensus estimate of ₹16.683 by -₹2.483.

Is Aurobindo Pharma Ltd overvalued?

According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aurobindo Pharma Ltd pay dividends?

Aurobindo Pharma Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.38%. See more information on Aurobindo Pharma Ltd dividends here

What is Aurobindo Pharma Ltd’s EPS estimate?

Aurobindo Pharma Ltd’s EPS estimate is 15.58.

How many shares outstanding does Aurobindo Pharma Ltd have?

Aurobindo Pharma Ltd has 580,801,640 shares outstanding.

What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?

Aurobindo Pharma Ltd reported an EPS of ₹14.2 in its last earnings report, missing expectations of ₹16.683. Following the earnings report the stock price went up 1.038%.

Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?

Currently, no hedge funds are holding shares in IN:AUROPHARMA

Company Description

Aurobindo Pharma Ltd

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Aurobindo Pharma Ltd (AUROPHARMA) Earnings & Revenues

Historic Earnings Reports

AUROPHARMA Stock 12 Month Forecast

Average Price Target

₹1,215.17

▲(16.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1009":"₹1,009","1548":"₹1,548","1143.75":"₹1,143.8","1278.5":"₹1,278.5","1413.25":"₹1,413.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1460,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.46K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1215.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.22K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1010,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.01K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1009,1143.75,1278.5,1413.25,1548],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1075.66,1105.2246153846154,1134.789230769231,1164.3538461538462,1193.9184615384615,1223.483076923077,1253.0476923076924,1282.6123076923077,1312.1769230769232,1341.7415384615385,1371.3061538461538,1400.8707692307694,1430.4353846153847,{"y":1460,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1075.66,1086.3915384615386,1097.123076923077,1107.8546153846155,1118.5861538461538,1129.3176923076924,1140.049230769231,1150.7807692307692,1161.5123076923078,1172.2438461538463,1182.9753846153847,1193.7069230769232,1204.4384615384615,{"y":1215.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1075.66,1070.6092307692309,1065.5584615384616,1060.5076923076924,1055.4569230769232,1050.406153846154,1045.3553846153848,1040.3046153846153,1035.253846153846,1030.2030769230769,1025.1523076923077,1020.1015384615384,1015.0507692307692,{"y":1010,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1426.89,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1547.39,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1433.17,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1390.78,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1250.55,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1346.34,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1346.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1167.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1053.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1224.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1132,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1128.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1075.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >